Milla K Mörsky, Reita H Nyberg, Maarit H Vuento, Synnöve Staff, Ilkka S Kaartinen
{"title":"初次手术中外阴癌患者的肿瘤预后、手术边缘和辅助治疗延迟。","authors":"Milla K Mörsky, Reita H Nyberg, Maarit H Vuento, Synnöve Staff, Ilkka S Kaartinen","doi":"10.1016/j.ijgc.2025.101942","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>As vulvar reconstruction has been proposed to improve surgical margins and could affect the timing of adjuvant therapy in patients with vulvar cancer, we aimed to compare oncological outcomes, surgical margins, and adjuvant treatment delays of patients with or without a vulvar reconstruction in their primary vulvar cancer surgery.</p><p><strong>Methods: </strong>We conducted a retrospective, single-center study comprising patients who underwent surgery due to primary vulvar squamous cell carcinoma in Tampere University Hospital, Finland, in 2005-2018. The primary outcome was the number of vulvar recurrences. Secondary outcomes were time to vulvar recurrence, disease-free and overall survival, surgical margins, and adjuvant treatment delays.</p><p><strong>Results: </strong>Overall, 126 patients were included (reconstruction n = 37, direct closure n = 89). Median follow-up time was 46.0 (interquartile range [IQR] 15.5-102.0) vs 55.0 months (IQR 17.0-102.0) in the reconstruction and direct closure groups, respectively. Vulvar recurrences occurred in 18.9% vs 20.2% of patients, respectively (p = 0.87). Time to vulvar recurrence, disease-free survival, or overall survival were comparable between the groups despite an overrepresentation of large [40.0 mm (IQR 25.5-55.0) vs 20.0 mm (IQR 13.0-35.0), p < 0.001], medial (81.1% vs 56.2%, p = .008), multifocal (29.7% vs 7.9%, p = .001), deeply invasive tumors [8.0 mm (IQR; 4.5-14.5) vs 3.5 mm (IQR 2.0-8.0), p < .001] presenting with perineural (32.3% vs 13.6%, p = .035) and lymphovascular space invasion (42.9% vs 15.6%, p = .003) in the reconstruction group. Surgical margins did not differ between the groups despite differences in pathological characteristics. Adjuvant therapy was not delayed in the reconstruction group compared to direct closure group [median delay 59.0 (IQR 52.0-73.8) vs 61.0 days (IQR 50.0-66.0), p = .59], and there was no statistically significant difference in the need for adjuvant therapy.</p><p><strong>Conclusions: </strong>Vulvar reconstruction was associated with non-inferior oncological outcomes compared to the direct closure group, though this conclusion is limited by the retrospective nature of the study. Frequent co-operation between gynecologic oncologists and plastic surgeons is encouraged.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101942"},"PeriodicalIF":4.1000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oncological outcomes, surgical margins, and adjuvant treatment delays in vulvar cancer patients with or without reconstruction during primary surgery.\",\"authors\":\"Milla K Mörsky, Reita H Nyberg, Maarit H Vuento, Synnöve Staff, Ilkka S Kaartinen\",\"doi\":\"10.1016/j.ijgc.2025.101942\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>As vulvar reconstruction has been proposed to improve surgical margins and could affect the timing of adjuvant therapy in patients with vulvar cancer, we aimed to compare oncological outcomes, surgical margins, and adjuvant treatment delays of patients with or without a vulvar reconstruction in their primary vulvar cancer surgery.</p><p><strong>Methods: </strong>We conducted a retrospective, single-center study comprising patients who underwent surgery due to primary vulvar squamous cell carcinoma in Tampere University Hospital, Finland, in 2005-2018. The primary outcome was the number of vulvar recurrences. Secondary outcomes were time to vulvar recurrence, disease-free and overall survival, surgical margins, and adjuvant treatment delays.</p><p><strong>Results: </strong>Overall, 126 patients were included (reconstruction n = 37, direct closure n = 89). Median follow-up time was 46.0 (interquartile range [IQR] 15.5-102.0) vs 55.0 months (IQR 17.0-102.0) in the reconstruction and direct closure groups, respectively. Vulvar recurrences occurred in 18.9% vs 20.2% of patients, respectively (p = 0.87). Time to vulvar recurrence, disease-free survival, or overall survival were comparable between the groups despite an overrepresentation of large [40.0 mm (IQR 25.5-55.0) vs 20.0 mm (IQR 13.0-35.0), p < 0.001], medial (81.1% vs 56.2%, p = .008), multifocal (29.7% vs 7.9%, p = .001), deeply invasive tumors [8.0 mm (IQR; 4.5-14.5) vs 3.5 mm (IQR 2.0-8.0), p < .001] presenting with perineural (32.3% vs 13.6%, p = .035) and lymphovascular space invasion (42.9% vs 15.6%, p = .003) in the reconstruction group. Surgical margins did not differ between the groups despite differences in pathological characteristics. Adjuvant therapy was not delayed in the reconstruction group compared to direct closure group [median delay 59.0 (IQR 52.0-73.8) vs 61.0 days (IQR 50.0-66.0), p = .59], and there was no statistically significant difference in the need for adjuvant therapy.</p><p><strong>Conclusions: </strong>Vulvar reconstruction was associated with non-inferior oncological outcomes compared to the direct closure group, though this conclusion is limited by the retrospective nature of the study. Frequent co-operation between gynecologic oncologists and plastic surgeons is encouraged.</p>\",\"PeriodicalId\":14097,\"journal\":{\"name\":\"International Journal of Gynecological Cancer\",\"volume\":\"35 7\",\"pages\":\"101942\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecological Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijgc.2025.101942\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2025.101942","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:由于外阴重建术被认为可以改善外阴癌患者的手术切缘,并可能影响外阴癌患者辅助治疗的时机,我们的目的是比较进行外阴重建术或不进行外阴重建术的原发性外阴癌患者的肿瘤预后、手术切缘和辅助治疗延迟。方法:我们进行了一项回顾性、单中心研究,包括2005-2018年在芬兰坦佩雷大学医院因原发性外阴鳞状细胞癌接受手术的患者。主要结果是外阴复发的数量。次要结局是外阴复发时间、无病生存和总生存、手术切缘和辅助治疗延迟。结果:共纳入126例患者(重建37例,直接闭合89例)。重建组和直接闭合组的中位随访时间分别为46.0个月(四分位间距[IQR] 15.5-102.0)和55.0个月(IQR 17.0-102.0)。外阴复发率分别为18.9%和20.2% (p = 0.87)。尽管大肿瘤[40.0 mm (IQR 25.5-55.0) vs 20.0 mm (IQR 13.0-35.0), p < 0.001]、内侧肿瘤(81.1% vs 56.2%, p = 0.008)、多灶性肿瘤(29.7% vs 7.9%, p = 0.001)、深部浸润性肿瘤[8.0 mm (IQR;4.5-14.5) vs 3.5 mm (IQR 2.0-8.0), p < 0.001),重建组表现为神经周围(32.3% vs 13.6%, p = 0.035)和淋巴血管间隙侵犯(42.9% vs 15.6%, p = 0.003)。尽管病理特征不同,但两组间手术切缘无差异。与直接闭合组相比,重建组辅助治疗无延迟[中位延迟59.0 (IQR 52.0-73.8) vs 61.0天(IQR 50.0-66.0), p = 0.59],辅助治疗需求无统计学差异。结论:与直接闭合组相比,外阴重建术与非劣性肿瘤预后相关,尽管这一结论受到研究回顾性的限制。鼓励妇科肿瘤学家和整形外科医生之间的频繁合作。
Oncological outcomes, surgical margins, and adjuvant treatment delays in vulvar cancer patients with or without reconstruction during primary surgery.
Objective: As vulvar reconstruction has been proposed to improve surgical margins and could affect the timing of adjuvant therapy in patients with vulvar cancer, we aimed to compare oncological outcomes, surgical margins, and adjuvant treatment delays of patients with or without a vulvar reconstruction in their primary vulvar cancer surgery.
Methods: We conducted a retrospective, single-center study comprising patients who underwent surgery due to primary vulvar squamous cell carcinoma in Tampere University Hospital, Finland, in 2005-2018. The primary outcome was the number of vulvar recurrences. Secondary outcomes were time to vulvar recurrence, disease-free and overall survival, surgical margins, and adjuvant treatment delays.
Results: Overall, 126 patients were included (reconstruction n = 37, direct closure n = 89). Median follow-up time was 46.0 (interquartile range [IQR] 15.5-102.0) vs 55.0 months (IQR 17.0-102.0) in the reconstruction and direct closure groups, respectively. Vulvar recurrences occurred in 18.9% vs 20.2% of patients, respectively (p = 0.87). Time to vulvar recurrence, disease-free survival, or overall survival were comparable between the groups despite an overrepresentation of large [40.0 mm (IQR 25.5-55.0) vs 20.0 mm (IQR 13.0-35.0), p < 0.001], medial (81.1% vs 56.2%, p = .008), multifocal (29.7% vs 7.9%, p = .001), deeply invasive tumors [8.0 mm (IQR; 4.5-14.5) vs 3.5 mm (IQR 2.0-8.0), p < .001] presenting with perineural (32.3% vs 13.6%, p = .035) and lymphovascular space invasion (42.9% vs 15.6%, p = .003) in the reconstruction group. Surgical margins did not differ between the groups despite differences in pathological characteristics. Adjuvant therapy was not delayed in the reconstruction group compared to direct closure group [median delay 59.0 (IQR 52.0-73.8) vs 61.0 days (IQR 50.0-66.0), p = .59], and there was no statistically significant difference in the need for adjuvant therapy.
Conclusions: Vulvar reconstruction was associated with non-inferior oncological outcomes compared to the direct closure group, though this conclusion is limited by the retrospective nature of the study. Frequent co-operation between gynecologic oncologists and plastic surgeons is encouraged.
期刊介绍:
The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.